Outlook Therapeutics (OTLK) Interest Expenses (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Interest Expenses of $49447.0 for Q1 2026, up 21.53% year-over-year from $40686.0 in Q1 2025, and down 96.67% quarter-over-quarter from $1.5 million in Q4 2025.
Outlook Therapeutics (OTLK) Interest Expenses (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Interest Expenses for 12 consecutive years, with $49447.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 21.53% year-over-year to $49447.0; the TTM figure through Mar 2026 stood at $49447.0 (up 109.77% YoY), while the FY2025 annual figure was $145.9 million, up 5.13% from the prior year.
- Interest Expenses slipped to $49447.0 in Q1 2026 per OTLK's latest filing, from $1.5 million in the prior quarter.
- Across five years, Interest Expenses topped out at $102.6 million in Q3 2022 and bottomed at -$1.0 million in Q3 2023.
- Historically, Interest Expenses has averaged $7.3 million across 5 years, with a median of $475000.0 in 2024.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 890710.26% — and 2023, when it slumped 101.0%.
- Outlook Therapeutics' Interest Expenses stood at $2.1 million in 2022, then tumbled by 85.16% to $307927.0 in 2023, then plunged by 72.82% to $83680.0 in 2024, then surged by 1676.34% to $1.5 million in 2025, then tumbled by 96.67% to $49447.0 in 2026.
- Business Quant data shows OTLK's Interest Expenses at $49447.0 in Q1 2026, $1.5 million in Q4 2025, and $77315.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,447.00 |
| Mar 31, 2026 | 49,447.00 |
| Dec 31, 2025 | 1.49 Mn |
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 77,315.00 |
| Sep 30, 2025 | 77,315.00 |
| Jun 30, 2025 | 83,680.00 |
| Jun 30, 2025 | 83,680.00 |
| Mar 31, 2025 | 40,686.00 |
| Mar 31, 2025 | 40,686.00 |
| Dec 31, 2024 | 83,680.00 |
| Dec 31, 2024 | 83,680.00 |
| Sep 30, 2024 | -117.00 |
| Sep 30, 2024 | -117.00 |
| Jun 30, 2024 | 636,830.00 |
| Jun 30, 2024 | 636,830.00 |
| Mar 31, 2024 | 475,000.00 |
| Mar 31, 2024 | 475,000.00 |
| Dec 31, 2023 | 307,927.00 |
| Dec 31, 2023 | 307,927.00 |